Actelion shares are on the rise again on reports of a potential counter-bid from France's Sanofi.
I spent the weekend with thousands of blood disease researchers. This is what happened.
Check out the weekly charts and key levels for 11 S&P 500 Sector exchange-traded funds.
The second major insurance merger trial begins Monday.
The powerful rally off the November lows has pushed UnitedHealth into extremely overbought territory.
Juno now finds itself one year, if not two years or more, behind rivals Novartis and Kite.
While a phase III study progresses, Acceleron is searching for different populations of MDS patients where luspatercept might also be effective.
Shares of these three companies were big winners following the election last month and have the best long-term growth prospects.
Teleflex has agreed to acquire the medical device company for about $1 billion after the target and its CEO were acquitted in a criminal case earlier in the year.
Leonard Schleifer says his company has worked under six administrations and hopes to continue his mission for a fair balance on drug prices.
Despite broad bipartisan support, a measure that includes $6.3 billion in new healthcare spending is still drawing protests from some in the Senate who vote next week on its fate.
Shares of Aradigm plunged, after the pharmaceutical company released mixed results for its inhaled antibiotic Pulmaquin.
The Affordable Care Act, popularly called Obamacare, helped health insurers Aetna, Humana, Anthem and Cigna. Then rising costs hurt them. Now shares could rebound further.
'We're seeing impressive, early responses with BB2121 without the toxicity,' says Bluebird CEO Nick Leschly.
It's a moot point whether ACA is good policy or not. It's a goner, which makes this health care company a shrewd investment now.